查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1837136

結核病診斷市場按產品、技術、檢測類型、最終用戶和應用分類－2025-2032年全球預測

Tuberculosis Diagnostics Market by Product, Technology, Test Type, End User, Application - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，結核病診斷市場規模將達到 49.3 億美元，複合年成長率為 5.65%。

關鍵市場統計數據
基準年2024年 31.7億美元
預計年份：2025年 33.5億美元
預測年份 2032 49.3億美元
複合年成長率 (%) 5.65%

引言部分重點介紹了影響整個醫療保健系統結核病診斷和決策的當代臨床、實驗室和政策因素。

結核病（TB）是一項重大的公共衛生挑戰，需要臨床、實驗室和公共衛生系統之間協調一致的診斷應對措施。診斷領域錯綜複雜，涵蓋各種技術、檢體處理流程和最終用戶，每個環節都會影響臨床決策和病患預後。隨著診斷工具的不斷發展，從臨床醫生到參考實驗室的相關人員必須應對不斷變化的法規環境、供應鏈動態以及疾病流行病學的演變。因此，對當前趨勢和策略意義進行簡明扼要的總結將有助於更明智地分配資源和技術應用選擇。

本執行摘要整合了影響診斷實務和採購的各項交叉主題，重點闡述了技術進步、營運瓶頸和政策促進因素。它還著重強調了影響採購週期和臨床效用，涵蓋從耗材到設備、從分子平台到非分子平台等各個方面。本書將這些洞見融入當代臨床優先事項，為負責大規模部署診斷並將其整合到更廣泛的醫療服務路徑中的領導者提供參考。摘要，本書從描述性背景入手，逐步深入到策略性啟示，闡述了各機構如何在保持以患者為中心的治療效果和系統韌性的同時，使投資與不斷變化的診斷需求保持一致。

快速的分子創新、數位影像技術的進步以及系統互通性如何重塑結核病診斷和臨床路徑

結核病診斷領域正經歷一系列變革性轉變，其驅動力包括技術創新、不斷變化的臨床重點以及現代化診療實踐。分子技術，特別是快速核酸增幅檢查和基因分型檢測，正從專業標準化走向更分散的應用，從而縮短了檢測結果的獲取時間，並有助於更早做出治療決策。同時，非分子診斷方法，例如數位放射成像，在人工智慧和改進的免疫分析技術的輔助下，不斷完善病例發現和分診策略，從而構建出更多層次的診斷路徑，以平衡敏感性、特異性和資源限制。

同時，整合趨勢正在改變醫療保健系統內診斷服務的提供方式。實驗室越來越重視與電子健康記錄和實驗室資訊系統的互通性，而照護現場優先考慮易用性和遠端監測的連接性。這一轉變與政策和項目的調整相輔相成，這些調整優先考慮快速檢測抗藥性菌株、改善患者與醫療服務的銜接，並支持在高負擔人群中主動發現病例。因此，醫療服務提供者和採購團隊面臨著有關技術配置、培訓需求和長期營運永續性的新決策，這促使他們重新評估投資重點和實施藍圖。

評估美國關稅於2025年生效後對診斷採購、供應鏈韌性和供應商策略的累積營運和採購影響。

2025年關稅及貿易政策調整的實施對診斷價值鏈各環節的籌資策略、供應商選擇和零件採購都產生了影響。關稅壓力往往導致進口設備和耗材的到岸成本上升，迫使實驗室管理人員和採購負責人重新審視供應商合約並考慮其他籌資策略。為此，許多相關人員尋求區域供應商、簽訂長期供應商協議並增加庫存緩衝，以降低成本波動和運輸延誤的風險。

此外，由於製造商尋求盡可能減少貿易壁壘的影響，關稅可能會加速供應商多元化和本地化生產。從長遠來看，這種轉變可能會改變供應鏈，並鼓勵在更靠近需求中心的地方投資生產能力。同時，監管機構和採購方越來越重視供應鏈透明度、合約彈性和緊急應變計畫，以確保診斷服務的連續性。綜上所述，這些發展凸顯了採購團隊和企業負責人在確保緊急時應對計畫獲得臨床效能和診斷工具的同時，將貿易政策情境納入營運規劃的必要性。

將產品類型、技術等級、測試目的、最終用戶偏好和臨床用途與籌資策略和營運策略聯繫起來的詳細細分分析

了解市場細分對於使產品策略與臨床效用和採購週期保持一致至關重要。按產品類型分類，市場涵蓋耗材和儀器。耗材包括套件和試劑，其重複使用特性決定了持續的採購決策和低溫運輸物流。儀器則需要資本規劃、安裝和維護，因此採購選擇通常反映了長期的臨床工作流程和服務協議。這種產品層面的差異化也會影響供應商合約、保固制度和培訓承諾。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 整合基於 CRISPR 的照護現場技術以快速檢測結核病
  • 將人工智慧增強影像技術應用於結核病篩檢中痰塗片的自動分析
  • 擴大攜帶式分子診斷平台規模，以便在偏遠地區進行社區結核病篩檢
  • 全球推廣多重核酸增幅檢查用於檢測抗藥性結核病
  • 次世代定序的出現，為全面的抗藥性分析和流行病學追蹤提供了可能。
  • 開發一種基於呼吸的揮發性有機化合物感測器，用於在照護端進行非侵入性結核病篩檢
  • 將具備診斷功能的數位健康平台整合到結核病即時監測和管理中
  • 政府補貼計畫促進高負擔地區採用快速分子結核病檢測方法
  • 診斷設備製造商與非政府組織建立策略夥伴關係，加速普及低成本結核病檢測
  • 新興市場新型照護現場分子診斷的監管核准趨勢

第6章美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 結核病診斷產品市場

  • 消耗品
    • 套件
    • 試劑
  • 裝置

9. 按技術分類的結核病診斷市場

  • 分子
    • 基因型檢測
    • 核酸增幅檢查
  • 非分子
    • 影像學
    • 免疫學檢測

第10章 依檢測類型分類的結核病診斷市場

  • 檢測測試
    • 血液檢查
    • 培養試驗
    • 分子檢測
    • 皮膚測試
    • 塗片顯微鏡檢查
  • 藥物敏感性試驗
    • 分子Dst
    • 表現型 Dst

第11章 結核病診斷市場（以最終用戶分類）

  • 診所
  • 醫院
  • 參考實驗室

第12章 按應用分類的結核病診斷市場

  • 活動性結核病
    • 肺外結核病
    • 肺結核
  • 潛伏性結核病

13. 各地區結核病診斷市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 結核病診斷市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各國結核病診斷市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Cepheid, Inc.
    • Becton, Dickinson and Company
    • Hain Lifescience GmbH
    • Molbio Diagnostics Private Limited
    • bioMerieux SA
    • Abbott Molecular Inc.
    • Thermo Fisher Scientific Inc.
    • Roche Diagnostics International AG
    • QIAGEN NV
    • Hologic, Inc.
Product Code: MRR-03252A5F9274

The Tuberculosis Diagnostics Market is projected to grow by USD 4.93 billion at a CAGR of 5.65% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 3.17 billion
Estimated Year [2025] USD 3.35 billion
Forecast Year [2032] USD 4.93 billion
CAGR (%) 5.65%

A focused introduction that frames contemporary clinical, laboratory, and policy drivers shaping tuberculosis diagnostics and decision-making across healthcare systems

Tuberculosis remains a critical public health challenge that demands a coordinated diagnostic response across clinical, laboratory, and public health systems. The diagnostic landscape encompasses a broad array of technologies, specimen workflows, and end users, each of which influences clinical decision-making and patient outcomes. As diagnostic tools evolve, stakeholders from clinicians to reference laboratories must navigate changing regulatory environments, supply chain dynamics, and shifting disease epidemiology. Consequently, a concise synthesis of current trends and strategic implications supports more informed resource allocation and technology adoption choices.

This executive summary synthesizes cross-cutting themes that shape diagnostic practice and procurement, emphasizing technological advances, operational bottlenecks, and policy drivers. It also highlights segmentation-specific considerations that affect procurement cycles and clinical utility, spanning consumables through instruments and molecular through nonmolecular platforms. By framing these insights within contemporary clinical priorities, the narrative informs leaders who are responsible for deploying diagnostics at scale and integrating them into broader care pathways. Moving from descriptive context to strategic implications, the summary outlines how organizations can align investments with evolving diagnostic needs while maintaining patient-centered outcomes and system resilience.

How rapid molecular innovation, digital imaging advances, and system interoperability are reshaping tuberculosis diagnostics and clinical pathways in practice

The diagnostic landscape for tuberculosis is undergoing a series of transformative shifts driven by technological innovation, evolving clinical priorities, and operational modernization. Molecular techniques, particularly rapid nucleic acid amplification tests and genotypic assays, have moved from specialized reference settings toward more decentralized use, reducing time-to-result and enabling earlier therapeutic decisions. At the same time, nonmolecular modalities such as digital radiography augmented with artificial intelligence and improved immunological assays continue to refine case-finding and triage strategies, enabling a more layered diagnostic pathway that balances sensitivity, specificity, and resource constraints.

Concurrently, integration trends are changing how diagnostics are delivered within health systems. Laboratories increasingly emphasize interoperability with electronic medical records and laboratory information systems, while point-of-care deployments prioritize ease of use and connectivity for remote monitoring. These shifts are complemented by policy and programmatic changes that prioritize rapid detection of drug-resistant strains, improve linkage-to-care, and support active case finding in high-burden populations. As a result, healthcare providers and procurement teams face new decisions about technology mix, training needs, and long-term operational sustainability, prompting a re-evaluation of investment priorities and implementation roadmaps.

Assessing the cumulative operational and procurement ramifications of United States tariffs introduced in 2025 on diagnostics sourcing, supply chain resilience, and vendor strategies

The introduction of tariffs and trade policy adjustments in 2025 has influenced procurement strategies, supplier selection, and component sourcing within the diagnostics value chain. Tariff pressures tend to increase landed costs for imported instruments and consumables, prompting laboratory managers and procurement officers to reassess vendor contracts and consider alternative sourcing strategies. In response, many stakeholders have explored regional suppliers, long-term supplier agreements, and increased inventory buffers to mitigate the risk of cost volatility and shipment delays.

Moreover, tariffs can accelerate supplier diversification and local manufacturing initiatives as manufacturers seek to minimize exposure to trade barriers. This shift may alter supply networks over time and encourage investment in manufacturing capabilities closer to demand centers. Simultaneously, regulatory authorities and purchasers have placed greater emphasis on supply chain transparency, contract flexibility, and contingency planning to maintain continuity of diagnostic services. Collectively, these developments underscore the need for procurement teams and corporate strategists to incorporate trade policy scenarios into operational planning while preserving clinical performance and timely access to diagnostic tools.

Detailed segmentation analysis linking product types, technology classes, test purposes, end-user settings, and clinical applications to procurement and operational strategies

Understanding segmentation is essential for aligning product strategy with clinical utility and procurement cycles. Based on product, the market spans consumables and instruments, with consumables comprising kits and reagents whose recurring nature drives ongoing purchasing decisions and cold-chain logistics. Instruments require capital planning, installation, and maintenance programs, and therefore procurement choices often reflect longer-term clinical workflows and service agreements. This product-level differentiation also influences supplier contracts, warranty structures, and training commitments.

Based on technology, the landscape divides into molecular and nonmolecular approaches. Molecular technologies include genotypic assays and nucleic acid amplification tests that excel in rapid detection and resistance profiling, while nonmolecular approaches encompass imaging modalities and immunological assays that support screening, triage, and latent infection assessment. Each technology pathway has distinct operational characteristics relating to sample handling, throughput, and laboratory biosafety requirements. Based on test type, diagnostics are categorized into detection tests and drug susceptibility testing. Detection tests include blood tests, culture-based tests, molecular tests, skin tests, and smear microscopy; they guide initial diagnosis and case identification. Drug susceptibility testing is further distinguished into molecular DST and phenotypic DST, both of which are critical for informing effective treatment regimens and public health containment strategies.

Based on end user, deployment considerations vary across clinics, hospitals, and reference laboratories. Clinics often prioritize ease of use and rapid turnaround to support point-of-care decisions, hospitals balance throughput and comprehensive reporting for inpatient care, and reference laboratories handle complex assays and confirmatory testing. Based on application, the diagnostic pathway differentiates between active tuberculosis and latent tuberculosis, where active disease further segments into extrapulmonary and pulmonary presentations; these clinical distinctions dictate specimen types, diagnostic algorithms, and downstream clinical management. Taken together, these segmentation lenses inform procurement priorities, capacity planning, and clinical integration strategies that stakeholders must reconcile when designing diagnostic networks.

Comparative regional perspectives on diagnostic access, implementation priorities, and capacity-building imperatives across the Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics shape diagnostic availability, adoption patterns, and implementation priorities across geographies. In the Americas, strong laboratory infrastructure in many urban centers enables adoption of rapid molecular diagnostics and integration with electronic health records, while outreach to underserved and rural communities emphasizes point-of-care technologies and mobile screening initiatives. Meanwhile, programmatic priorities increasingly address the intersection of tuberculosis with comorbidities and vulnerable populations, which influences specimen referral networks and clinician training programs.

In Europe, Middle East & Africa, heterogeneous health system capacity drives a mixed-pace adoption pattern where advanced centralized laboratories coexist with resource-constrained peripheral sites. This region places high importance on capacity-building, procurement collaborations, and regulatory alignment to ensure quality and consistency across borders. Investments in decentralization are balanced against the need to maintain quality assurance and confirmatory testing pathways. In the Asia-Pacific, high-burden settings have catalyzed rapid uptake of point-of-care molecular diagnostics, strengthened laboratory networks, and prioritized strategies for drug-resistant tuberculosis. Regional manufacturers and public-private partnerships play a significant role in scaling access, while digital health initiatives and community-based screening programs complement diagnostic investments. Across regions, cross-cutting themes such as supply chain resilience, workforce development, and the harmonization of diagnostic algorithms remain central to successful implementation.

Company-level dynamics highlighting strategic partnerships, technological specialization, and the operational capabilities that drive diagnostic adoption and sustainability

A mix of established multinational diagnostic manufacturers and specialized innovators drives technological progress and market dynamics. Manufacturers of molecular platforms have prioritized assay expansion, throughput enhancement, and connectivity features to meet the needs of diverse laboratory footprints. Simultaneously, companies focused on consumables and reagents emphasize quality control, lot-to-lot consistency, and logistical reliability to support uninterrupted testing programs. There is also a notable rise in specialized firms developing targeted assays for drug resistance markers and rapid susceptibility profiling, responding to clinical demand for faster therapeutic guidance.

Strategic partnerships between instrument providers and reagent suppliers have become more common, as they streamline procurement and service delivery for health systems. Innovators in digital radiography and artificial intelligence have pursued integrations with laboratory workflows to improve triage efficiency, while contract service providers and maintenance networks play an important role in sustaining equipment uptime, particularly in decentralized settings. Across the competitive landscape, companies that demonstrate robust regulatory compliance, dependable supply chains, and scalable training models tend to achieve wider clinical adoption. Looking ahead, collaboration between diagnostics developers, clinical researchers, and implementation partners will be essential to translate technical advances into routine clinical practice and public health impact.

Actionable strategic imperatives for diagnostics leaders to strengthen portfolios, supply chains, workforce capability, data integration, and stakeholder partnerships

Industry leaders should adopt a multi-pronged strategy that balances innovation, operational resilience, and stakeholder engagement. First, prioritize modular technology portfolios that allow rapid adaptation to changing clinical needs without requiring complete platform replacement. This approach reduces obsolescence risk and enables laboratories to scale specific assays as clinical demand evolves. Second, strengthen supply chain visibility by formalizing multi-supplier agreements, regional stocking strategies, and service-level commitments to reduce vulnerability to trade disruptions and component shortages.

Third, invest in workforce development and remote-support capabilities to ensure that technicians and clinicians can effectively use advanced diagnostics, interpret complex results, and maintain quality standards. Fourth, pursue interoperability and data integration initiatives that tie diagnostics into broader care pathways, enabling faster clinical action and improved surveillance. Fifth, engage proactively with regulatory bodies and payors to clarify reimbursement pathways and evidence requirements that support adoption. Finally, cultivate collaborative partnerships with public health programs and community providers to align diagnostic deployment with screening, contact tracing, and treatment-support strategies. Together, these steps will position organizations to respond nimbly to both clinical imperatives and operational challenges.

A transparent, multi-source research methodology integrating stakeholder interviews, clinical evidence, regulatory guidance, and supply chain assessments to validate insights

The research synthesized here draws on a structured and transparent methodology that integrates multiple evidence streams to support robust insight development. Primary inputs include stakeholder interviews with laboratory directors, clinicians, procurement officers, and manufacturer representatives, which provide first-hand perspectives on operational challenges and adoption drivers. These qualitative insights are complemented by systematic reviews of peer-reviewed clinical literature, technical guidance from authoritative public health agencies, and regulatory approvals that contextualize technology performance and intended use.

Additionally, the approach incorporates supply chain analysis and procurement practice reviews to assess sourcing vulnerabilities and logistical considerations. Comparative technology assessments evaluate assay performance characteristics, sample handling requirements, and implementation complexity to inform deployment scenarios. Throughout the research process, triangulation across data types ensured consistency of findings and highlighted areas of divergence for further exploration. Emphasis was placed on reproducibility of methods, explicit documentation of assumptions, and validation of insights with subject-matter experts to ensure practical relevance for decision-makers.

A succinct conclusion emphasizing the convergence of technology advances, operational resilience, and collaborative implementation to improve tuberculosis diagnostic outcomes

In synthesis, tuberculosis diagnostics are at an inflection point where technological advancements, regional implementation dynamics, and supply chain considerations converge to redefine diagnostic pathways. Molecular and nonmolecular technologies complement one another, enabling a layered approach to detection, triage, and resistance profiling that can improve clinical outcomes when integrated thoughtfully into care systems. At the same time, procurement strategies and operational practices must adapt to geopolitical developments and evolving demand patterns to preserve timely access to essential diagnostics.

Consequently, stakeholders who combine a strategic focus on adaptable technology portfolios, robust supply chain planning, workforce capacity-building, and regional implementation alignment will be best positioned to translate diagnostic innovation into sustained clinical and public health impact. Continued collaboration among manufacturers, health systems, and public health authorities will be critical to ensure that technological promise results in measurable improvements in diagnosis, treatment initiation, and containment of drug-resistant tuberculosis.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of CRISPR-based point-of-care assays for rapid tuberculosis detection
  • 5.2. Expansion of AI-enhanced imaging technologies for automated sputum smear analysis in TB screening
  • 5.3. Scaling up portable molecular diagnostic platforms to enable community-based TB screening in remote areas
  • 5.4. Adoption of multiplexed nucleic acid amplification tests for drug resistant TB detection worldwide
  • 5.5. Emergence of next generation sequencing for comprehensive resistance profiling and epidemiological tracing
  • 5.6. Development of breath based volatile organic compound sensors for non invasive TB screening at point of care
  • 5.7. Integration of digital health platforms with diagnostics for real time TB case monitoring and management
  • 5.8. Government subsidy programs driving adoption of rapid molecular TB tests in high burden regions
  • 5.9. Strategic partnerships between diagnostic manufacturers and NGOs to accelerate low cost TB test distribution
  • 5.10. Trend of regulatory approvals for novel point of care TB molecular diagnostics in emerging markets

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Tuberculosis Diagnostics Market, by Product

  • 8.1. Consumables
    • 8.1.1. Kits
    • 8.1.2. Reagents
  • 8.2. Instruments

9. Tuberculosis Diagnostics Market, by Technology

  • 9.1. Molecular
    • 9.1.1. Genotypic Assays
    • 9.1.2. Nucleic Acid Amplification Tests
  • 9.2. Nonmolecular
    • 9.2.1. Imaging
    • 9.2.2. Immunological Assays

10. Tuberculosis Diagnostics Market, by Test Type

  • 10.1. Detection Test
    • 10.1.1. Blood Tests
    • 10.1.2. Culture-Based Tests
    • 10.1.3. Molecular Tests
    • 10.1.4. Skin Tests
    • 10.1.5. Smear Microscopy
  • 10.2. Drug Susceptibility Testing
    • 10.2.1. Molecular Dst
    • 10.2.2. Phenotypic Dst

11. Tuberculosis Diagnostics Market, by End User

  • 11.1. Clinics
  • 11.2. Hospitals
  • 11.3. Reference Laboratories

12. Tuberculosis Diagnostics Market, by Application

  • 12.1. Active Tb
    • 12.1.1. Extrapulmonary Tb
    • 12.1.2. Pulmonary Tb
  • 12.2. Latent Tb

13. Tuberculosis Diagnostics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Tuberculosis Diagnostics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Tuberculosis Diagnostics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Cepheid, Inc.
    • 16.3.2. Becton, Dickinson and Company
    • 16.3.3. Hain Lifescience GmbH
    • 16.3.4. Molbio Diagnostics Private Limited
    • 16.3.5. bioMerieux SA
    • 16.3.6. Abbott Molecular Inc.
    • 16.3.7. Thermo Fisher Scientific Inc.
    • 16.3.8. Roche Diagnostics International AG
    • 16.3.9. QIAGEN N.V.
    • 16.3.10. Hologic, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. TUBERCULOSIS DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. TUBERCULOSIS DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. TUBERCULOSIS DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY GENOTYPIC ASSAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY GENOTYPIC ASSAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY GENOTYPIC ASSAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY GENOTYPIC ASSAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY GENOTYPIC ASSAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY GENOTYPIC ASSAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY IMMUNOLOGICAL ASSAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY IMMUNOLOGICAL ASSAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY IMMUNOLOGICAL ASSAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY IMMUNOLOGICAL ASSAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY IMMUNOLOGICAL ASSAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY IMMUNOLOGICAL ASSAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY BLOOD TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY BLOOD TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY BLOOD TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY BLOOD TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY BLOOD TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY BLOOD TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CULTURE-BASED TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CULTURE-BASED TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CULTURE-BASED TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CULTURE-BASED TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CULTURE-BASED TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CULTURE-BASED TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY SKIN TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY SKIN TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY SKIN TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY SKIN TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY SKIN TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY SKIN TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY SMEAR MICROSCOPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY SMEAR MICROSCOPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY SMEAR MICROSCOPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY SMEAR MICROSCOPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY SMEAR MICROSCOPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY SMEAR MICROSCOPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR DST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR DST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR DST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR DST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR DST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR DST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PHENOTYPIC DST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PHENOTYPIC DST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PHENOTYPIC DST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PHENOTYPIC DST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PHENOTYPIC DST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PHENOTYPIC DST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY EXTRAPULMONARY TB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY EXTRAPULMONARY TB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY EXTRAPULMONARY TB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY EXTRAPULMONARY TB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY EXTRAPULMONARY TB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY EXTRAPULMONARY TB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PULMONARY TB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PULMONARY TB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PULMONARY TB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PULMONARY TB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PULMONARY TB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PULMONARY TB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY LATENT TB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY LATENT TB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY LATENT TB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY LATENT TB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY LATENT TB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY LATENT TB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 186. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 187. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 188. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 189. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 191. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 193. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2018-2024 (USD MILLION)
  • TABLE 194. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2025-2032 (USD MILLION)
  • TABLE 195. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2018-2024 (USD MILLION)
  • TABLE 196. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2025-2032 (USD MILLION)
  • TABLE 197. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 198. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 199. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2018-2024 (USD MILLION)
  • TABLE 200. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2025-2032 (USD MILLION)
  • TABLE 201. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2018-2024 (USD MILLION)
  • TABLE 202. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 207. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2025-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. NORTH AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 212. NORTH AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 214. NORTH AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 216. NORTH AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2018-2024 (USD MILLION)
  • TABLE 218. NORTH AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2025-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2018-2024 (USD MILLION)
  • TABLE 220. NORTH AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2025-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 222. NORTH AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2018-2024 (USD MILLION)
  • TABLE 224. NORTH AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2025-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2018-2024 (USD MILLION)
  • TABLE 226. NORTH AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2025-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 228. NORTH AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 230. NORTH AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2025-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. LATIN AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. LATIN AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 236. LATIN AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 237. LATIN AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 238. LATIN AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 240. LATIN AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2018-2024 (USD MILLION)
  • TABLE 242. LATIN AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2025-2032 (USD MILLION)
  • TABLE 243. LATIN AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2018-2024 (USD MILLION)
  • TABLE 244. LATIN AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2025-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 246. LATIN AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2018-2024 (USD MILLION)
  • TABLE 248. LATIN AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2025-2032 (USD MILLION)
  • TABLE 249. LATIN AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2018-2024 (USD MILLION)
  • TABLE 250. LATIN AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2025-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 252. LATIN AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 254. LATIN AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 255. LATIN AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2018-2024 (USD MILLION)
  • TABLE 256. LATIN AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2025-2032 (USD MILLION)
  • TABLE 299. EUROPE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 300. EUROPE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 301. EUROPE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 302. EUROPE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 303. EUROPE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2018-2024 (USD MILLION)
  • TABLE 304. EUROPE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2025-2032 (USD MILLION)
  • TABLE 305. MIDDLE EAST TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 306. MIDDLE EAST TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 307. MIDDLE EAST TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 308. MIDDLE EAST TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 309. MIDDLE EAST TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 310. MIDDLE EAST TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 311. MIDDLE EAST TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 312. MIDDLE EAST TUBERCULOS